More on Biotech
|13 Biotech Stocks Presenting New Data |
BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for May: May 1-6 Digestive Disease Week annual meeting. May 3-6 BIO International Convention. May 3-7 Amylin Pharmaceuticals ( AMLN), Eli Lilly ( LLY) and Alkermes ( ALKS) expected to hear back from FDA on new approval decision date for the diabetes drug Bydureon. Class 1 response means June date; Class 2 response means October date. Biotech Busts and Breakthroughs (Forbes) May 4 FDA approval decision date for InterMune's ( ITMN) Esbriet (pirfenidone) for treatment of idiopathic pulmonary fibrosis. Cleveland BioLabs ( CBLI) analyst/investor meeting. Vanda Pharmaceuticals ( VNDA - Get Report) first-quarter earnings, including update on commercial launch of the schizophrenia drug Fanapt. May 5 Allos Therapeutics ( ALTH) first-quarter earnings, including update on commercial launch of the lymphoma drug Folotyn. King Pharmaceuticals ( KG) first quarter earnings: Will King update investors on its pain drug partnership with Acura Pharmaceuticals ( ACUR)? May 6 Genzyme ( GENZ) analyst/investors meeting. FDA advisory panel to review Questcor Pharmaceuticals' ( QCOR) Acthar for infantile spasms. The FDA's briefing documents should be posted to the agency's web site on May 4 or May 5. Sequenom ( SQNM) first-quarter earnings. May 7 Mike Huckman's last day at CNBC. Good luck, Mike! Cytori Therapeutics ( CYTX) reports full, six-month results from Apollo trial (heart attack) and preliminary, six-month results from Precise (chronic ischemia) trial at Stem Cell Therapy and Cardiovascular Innovation conference. May 11 Merck ( MRK) analyst/investor meeting. May 14 Athersys ( ATHX) investor/analyst meeting. Cell Therapeutics ( CTIC) rescheduled shareholder meeting. Patent expiration for Taxotere, marketed by Sanofi-Aventis ( SNY). May 14-19 American Pain Society annual meeting. May 14-19 American Thoracic Society annual meeting. May 15-19 American College of Obstetricians and Gynecologists annual meeting. May 19-23 American Society of Gene and Cell Therapy May 22-27 American Psychiatric Association annual meeting. May 29 - June 3 American Urological Association annual meeting: The medical meeting debut of Dendreon's ( DNDN) Provenge as a fully approved prostate cancer immunotherapy! -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.